Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Clicks: 277
ID: 268642
2017
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In phase 3 trials of patients with HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients with HCV genotype 3 and cirrhosis. Mild gastrointestinal adverse …
Reference Key
im2017gastroenterologyefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jacobson IM;Lawitz E;Gane EJ;Willems BE;Ruane PJ;Nahass RG;Borgia SM;Shafran SD;Workowski KA;Pearlman B;Hyland RH;Stamm LM;Svarovskaia E;Dvory-Sobol H;Zhu Y;Subramanian GM;Brainard DM;McHutchison JG;Bräu N;Berg T;Agarwal K;Bhandari BR;Davis M;Feld JJ;Dore GJ;Stedman CAM;Thompson AJ;Asselah T;Roberts SK;Foster GR;;
Journal gastroenterology
Year 2017
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.